Congruence Therapeutics is working at the interface of computational and experimental drug discovery to design novel small molecules for diseases of protein misfolding. Congruence is building its own proprietary AI engine, Revenir, using publicly available and unique datasets by incorporating computational biophysics to tackle the protein misfolding problem in rare diseases. This purpose-built technology uses […]

View post to subscribe to site newsletter.

Perturba Therapeutics a oncology focused spin out from the University of Toronto advancing a pipeline of assets from undrugged protein-protein interactions (PPIs). Founded in 2021 as a venture between AI drug discovery company Cyclica and the Stagljar Lab at the University of Toronto, Perturba integrates Cyclica’s AI-augmented drug discovery platform with sensitive live cell-based technologies […]

View post to subscribe to site newsletter.

Alethiomics is an Oxford University spin-out applying innovations in single-cell multi-omic analysis to the development of novel therapeutics for myeloproliferative neoplasms (MPNs). MPNs are a group of chronic blood cancers that begin with mutations occurring in cancer stem cells in the bone marrow. While currently available treatments can relieve symptoms, they do not tackle the […]

View post to subscribe to site newsletter.